Reuters logo
BRIEF-Marinus announces successful clinical trial results
2017年9月11日 / 中午11点42分 / 2 个月前

BRIEF-Marinus announces successful clinical trial results

Sept 11 (Reuters) - Marinus Pharmaceuticals Inc

* Marinus announces successful clinical trial results and declares CDKL5 disorder its lead pediatric orphan epilepsy program for ganaxolone

* Marinus Pharmaceuticals Inc - ‍ganaxolone was generally safe and well-tolerated with no serious adverse events​

* Marinus Pharma- 1 child has not yet reached 26-week visit, 2 children discontinued prior to completing 26-week treatment due to lack of efficacy​

* Marinus Pharmaceuticals Inc - ‍there have been no adverse event reports of somnolence or dizziness​

* Marinus Pharmaceuticals Inc - has prioritized CDKL5 disorder as lead pediatric orphan program for advancement into later stage clinical development​‍​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below